http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f53846e5f1177ba9c2f5549bcc7b1460
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Gray |
| name | David Gray |
| given-name | David |
| organization-name | Institute of Electronic Structure and Laser (IESL), Foundation for Research and Technology Hellas (FORTH) D. Gray is at the Department of Immunology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK. Institute of Immunology and Infection Research 1 and 2 , and 3 and 4; Centre for Immunology, Infection and Evolution, School of Biological Sciences 1 and 2 , and 3 and 4; Medical Research Council Centre for Inflammation Research 1 and 2 , and 3 and 4; Centre for Multiple Sclerosis Research, University of Edinburgh, Edinburgh EH8 9YL, Scotland, UK 1 and 2 , and 3 and 4; Institute of Immunology and Infection Research 1 and 2 , and 3 and 4; Centre for Immunology, Infection and Evolution, School of Biological Sciences 1 and 2 , and 3 and 4; Medical Research Council Centre for Inflammation Research 1 and 2 , and 3 and 4; Centre for Multiple Sclerosis Research, University of Edinburgh, Edinburgh EH8 9YL, Scotland, UK 1 and 2 , and 3 and 4 Division of Cardiovascular Medicine, University Hospital, Nottingham. *Institute of Immunology and Infection Research, University of Edinburgh, Ashworth Laboratories, Edinburgh, United Kingdom; and Biopolymers and Colloids Research Laboratory, Department of Food Science, University of Massachusetts, Amherst, Massachusetts 01003, and Division of Food Sciences, University of Nottingham, Sutton Bonington Campus, Loughborough, Leics LE12 5RD, United Kingdom bInstitute of Cell, Animal and Population Biology, University of Edinburgh, Edinburgh EH9 3JT, United Kingdom Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; Wound Healing Practice, Development Unit, Birmingham City University, Birmingham Inscopix, Mountain View, CA, USA Department of Economics University of Ottawa Ottawa Ontario Canada Aberdeen Royal Infirmary and Consultant Editor, Tissue Viability Supplement, British Journal of Nursing †Institute of Cell, Animal and Population Biology, University of Edinburgh, Ashworth Laboratories, Edinburgh, United Kingdom; and (Tissue viability), Aberdeen Royal Infirmary Department of Tissue Viability, Grampian University Hospitals Trust Institute of Cell, Animal and Population Biology, University of Edinburgh, Ashworth Laboratories, King's Buildings, West Mains Road, Edinburgh EH9 3JT, UK Pfizer Inc., Cambridge, MA, USA; Current address: Cerevel Therapeutics, Boston, MA, USA Laboratory of Medicinal Chemistry, Department of Chemistry, Clemson University, Clemson, South Carolina 29634 Clinical Director, Healogics Ltd, and Professor of Tissue Viability, Wound Healing Practice Development Unit, Birmingham City University From the Department of Pharmaceutical Health Services Research (A.B.G., E.O., H.A., A.J.) and Department of Pharmacy Practice and Science (L.H.), University of Maryland School of Pharmacy, Baltimore; Pfizer Inc (D.E.M.), Collegeville, PA; Pfizer Inc (D.G.), Cambridge, MA; Pfizer Inc (J.A.), New York, NY; and Department of Neurology (L.M.S.), University of Maryland, School of Medicine, Baltimore. Ashworth Laboratories Institute of Immunology and Infection Research University of Edinburgh Edinburgh UK †Institute of Immunology and Infection Research and Centre for Immunity, Infection, and Evolution, University of Edinburgh, Edinburgh, United Kingdom Department of Tissue Viability, Grampian University Hospitals NHS Trust, and Consultant Editor, Tissue Viability Supplement, British Journal of Nursing C.T. Lamont Primary Health Care Research Centre, Elisabeth Bruyère Research Institute, Ottawa, Ontario. 2Institute of Cell Animal and Population Biology, University of Edinburgh, Ashworth Laboratories, Edinburgh EH93JT, United Kingdom Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K. School of Medicine; Keele University; Newcastle under Lyme Staffordshire UK University of Oxford Oxford UK Department of Tissue Viability, Aberdeen Royal Infirmary. IESL-FORTH, N. Plastira 100, 70013, Heraklion, Crete, Greece From the *Rheumatology Section and ‡Immunology Department, Division of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, United Kingdom; and the §Department of Human Genetics, Sloan Kettering Institute, New York 10021 School of Biological Sciences, University of EdinburghEdinburgh EH9 3JT, UK Institute of Immunology and Infection Research, School of Biological Sciences University of Edinburgh Edinburgh UK; Centre for Immunity, Infection and Evolution School of Biological Sciences, University of Edinburgh Edinburgh UK IESL-FORTH, N. Plastira 100, 70013 Heraklion, Crete, Greece School of Biological Sciences, Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, United Kingdom Department of Tissue Viability, Aberdeen and Clinical Director, Wounds-UK Department of Tissue Viability, Aberdeen Royal Infirmary, and Secondees to the Nursing and Midwifery Development Unit, Scotland *Institute of Immunology and Infection Research, School of Biological Sciences and; †Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh; and *Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom; and Tissue Viability Supplement, British Journal of Nursing Pfizer Inc., Cambridge, MA. Now with Cerevel Therapeutics. Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Ashworth Laboratories, King’s Buildings 2 , West Mains Road, Edinburgh EH9 3JT , UK Department of Tissue Viability, Grampian University Hospitals Trust, Aberdeen 1Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh EH9 3JT, UK Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, United Kingdom Francis King Carey School of Law, University of Maryland, Baltimore, MD 21201, USA *Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3JT, United Kingdom;; †Centre for Immunity, Infection, and Evolution, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3JT, United Kingdom; and *Department of Immunology, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom;; ‡Institute of Cell Animal and Population Biology, University of Edinburgh, Ashworth Laboratories, Edinburgh, United Kingdom Neuroscience Research Unit, Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States Department of Tissue Viability, Grampian University Hospital Trust, Aberdeen *Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, EH9 3JT, United Kingdom;; †Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh, EH9 3JT, United Kingdom; Institute of Cell, Animal, and Population Biology, University of Edinburgh, Edinburgh EH9 3JT United Kingdom Department of Chemistry, University of Natal, Durban, South Africa Managing Partner, Pioneer Sussex Wound Healing and Lymphoedema Centres / Professor of Wound Study, Wound Healing and Practice Development Unit, Birmingham City University Department of Tissue Viability, Aberdeen Royal Infirmary Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh EH9 3JT, United Kingdom. Institute of Electronic Structure and Laser; FORTH; 71110 Heraklion; Greece Lymphocyte Development Group, Gene Regulation and Chromatin Group, Haemostasis Group, Transplantation Biology Group, and Membrane Transport Biology Group, Medical Research Council Clinical Sciences Centre, Faculty of Medicine, Imperial College of Science, Technology, and Medicine, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, United Kingdom; and Institute of Cell, Animal, and Population Biology, University of Edinburgh, West Mains Road, Edinburgh EH9 3JT, United Kingdom Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Kings Buildings, West Mains Road, Edinburgh EH9 3JT, United Kingdom Department of Tissue Viability, Aberdeen Royal Infirmary, Aberdeen Chiron Corporation Emeryville California Drug Discovery Unit Wellcome Centre for Anti‐Infectives Research School of Life Sciences University of Dundee UK Institute of Immunology and Infection Research School of Biological Sciences, University of Edinburgh Edinburgh United Kingdom Department of Immunology, Royal Postgraduate Medical School, Du Cane Road, London, W12 0NN, United Kingdom Ocala Health/University of Central Florida Ocala, Florida *Department of Immunology, Division of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom; Olivia Newton‐John Cancer & Wellness Centre Austin Health Melbourne Victoria Australia (Tissue Viability), Aberdeen Royal Infirmary Institute of Cell, Animal and Population Biology, University of Edinburgh, Edinburgh EH9 3JT, United Kingdom Cerevel Therapeutics Research and Development, Boston, MA, USA From the Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, University of the Witwatersrand Medical School, Johannesburg, South Africa. S. Jainandunsing and D. Gray, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. |
Incoming Links
Total number of triples: 311.